Gut Microbiome Clinical Trial
Official title:
Effect of The Partial Substitution of Animal Protein by Soya-Based Fermented Product on Human Gut Microbiome and Clinical Health Markers
There is a growing understanding of the functioning and interconnectedness of microbiomes in the food system which offers great potential for enabling the development of new solutions contributing to achieving important food and nutrition goals including those requested by FOOD 2030. Of relevance in this regard is the provision of sustainable and healthy protein sources. Because of the obvious environmental and climate concerns associated with the production of animal-derived protein, a transition is needed to healthier and more environment-friendly diets, including a moderate-level consumption of red and processed meat and greater emphasis on plant-based foods. As well as impact of meat production on the climate, it is well established that eating a diet rich in red meat promotes the growth of gut microbiome members that drive or exacerbate inflammation. Plant protein does not have these associations, and in fact it is often accompanied by fibre ingestion, which favours growth of health-promoting gut microbes. Replacing meat with plant protein offers the prospect of improving consumer health by improving the gut microbiome. The EU funded project MICROBIOMES4SOY will assess the effect of replacing animal protein with soya-derived protein on the human gut microbiome and whether this replacement can reduce the risk of inflammation-related diseases by gut microbiome modulation. This knowledge will provide a baseline for establishing new dietary pathways making use of soya protein and support dietary transition for EU citizens.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | October 31, 2024 |
Est. primary completion date | October 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - Be able to give written informed consent. - Be between 18-55 years of age. - Has a BMI between >18.5 and <32.0 kg/m2. - Has a stable body weight (=5 % change) over the past 3-months. - Is in general good health, as determined by the investigator. - Consuming a single daily portion of red/processed meat in their Western diet as assessed by Food Frequency Questionnaire (meat items) at screening. - Willing to avoid lifestyle fluctuations (diet, exercise) for the duration of the study. Exclusion Criteria: - Participants who are pregnant or wish to become pregnant during the study. - Participants who are lactating and/or currently breastfeeding. - Participants currently of biological childbearing potential, but not using a continuous effective method of contraception. - Is hypersensitive to any of the components of the Study Product. - Participants who have taken oral antibiotics 12 weeks prior to visit 1. - Have a significant acute or chronic coexisting illness such as uncontrolled hypertension, uncontrolled hyperlipidaemia, hypercoagulation, inflammatory disorders, or any condition which contraindicates, in the investigator's judgement, entry to the study. - Metabolic or chronic diseases (including pre-diabetes and diabetes), metabolic syndrome, obesity (Class 2), uncontrolled high blood pressure or chronic inflammation or any ongoing medical condition that interferes significantly with absorption and digestion and/or gastrointestinal (GI) function. - Participants has acute or chronic gastrointestinal and/or infective disease (i.e., coeliac disease, diarrhoea, Crohn's disease, ulcerative colitis, irritable bowel syndrome, diverticulosis, stomach or duodenal ulcers, hepatitis, etc.), or with a history of such diseases or gastrointestinal surgery (appendectomy in the last 3 months acceptable). - Has a malignant disease or any concomitant end-stage organ disease, and are severely immunocompromised (HIV positive, transplant patient, on antirejection medications, or chemotherapy or radiotherapy which, in the Investigator's judgment, contraindicates participation in the study. - Participant has a history of drug and/or alcohol abuse at the time of enrolment (Drinks more than nationally recommended units per week (>11 units for women; >17 units for men); alcohol/substance abuse disorder). - Is a smoker/vaper/consumes or uses nicotine containing products. - Taking medications/supplements that the investigator believes would interfere with the objectives of the study. Prohibited medications include: - Metformin - Proton pump inhibitors - Protein supplements - Creatinine supplements - Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study. - Participants may not be receiving treatment involving experimental drugs/supplements. If the Participant has been in a recent experimental study, these must have been completed not less than 60 days prior to this study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University College Cork | AIT Austrian Institute of Technology GmbH |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the effect of replacing animal protein in a typical Western diet with plant-derived protein delivered in a (soy-based) tofu on gut microbiome composition. | Change from baseline (Week 0) to washout (Week 10) in gut microbiome composition as measured by shotgun metagenomics at weeks -2, 0,8 and 10. | 10 weeks | |
Secondary | To evaluate the functional activity of the gut microbiome, and any alterations caused by the soya replacement. | Change from baseline (Week 0) to end of intervention (Week 8) in functional activity of the gut microbiome as measured by stool meta transcriptomics in a population comprising of healthy males and females. | 8 weeks | |
Secondary | To evaluate the metabolome of urine and faecal samples and any alterations caused by the soya replacement. | Change from baseline (Week 0) to end of intervention (Week 8) on:
Urine metabolome (whole m/z ratio spectrum) Faecal metabolome (whole m/z ratio spectrum) Urine and Faecal metabolites will be measured using untargeted UHPLC-MS. |
8 weeks | |
Secondary | To measure the effect of the meat substitution on a panel of proinflammatory cytokines, based on the observation that particular taxa are associated with an inflammatory phenotype. | Change from baseline (Week 0) to end of intervention (Week 8) to measure the effect of the meat substitution on serum levels of the following inflammatory cytokines: TNF-alpha, IFN-alpha2, IL1b, IL3, IL4, IL6, IL7,IL8, IL22, CRP, CX3CL1 and Saa3 using MSD multiplex kits. | 8 weeks | |
Secondary | To measure the effect of the meat substitution on cholesterol and serum triglycerides. | Change from baseline (Week 0) to end of intervention (Week 8) on lipid profile:
Total cholesterol Triglycerides |
8 weeks | |
Secondary | To measure the effect of the meat substitution on blood pressure. | Change from baseline (Week 0) to end of intervention (Week 8) on blood pressure [systolic/diastolic blood pressure (mmHg)]. | 8 weeks | |
Secondary | To measure the effect of the meat substitution on body mass index (BMI). | Change from baseline (Week 0) to end of intervention (Week 8) on body mass index. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05793112 -
INF108F in Infants With Food Protein Induced Proctocolitis
|
Phase 4 | |
Active, not recruiting |
NCT04327141 -
Low Sugar Protein Pacing, Intermittent Fasting Diet in Men and Women
|
N/A | |
Recruiting |
NCT04117321 -
Mother-infant Microbiota Transmission and Its Link to the Health of the Baby
|
||
Recruiting |
NCT05655910 -
Enhanced Nutritional Optimization in LVAD Trial
|
N/A | |
Recruiting |
NCT03325855 -
Fecal Microbiota Transplant National Registry
|
||
Active, not recruiting |
NCT05931471 -
Yogurt and GI Health
|
N/A | |
Recruiting |
NCT03797417 -
Gut Microbiome and Metabolic Pathways Changes in Vitiligo
|
||
Withdrawn |
NCT06006416 -
Effect of Fenugreek Fibre on Gut Microbiome
|
Phase 3 | |
Recruiting |
NCT06206486 -
The Gut Microbiome and Serum Metabolites as a Biological Mechanism Underlying Pain in Kidney Transplantation
|
||
Completed |
NCT02655250 -
Neonatal Microbiome Validity Study
|
||
Recruiting |
NCT05670288 -
Impact of Gut Microbiome on Metabolic and Bowel Function During the First Year After Spinal Cord Injury
|
||
Not yet recruiting |
NCT03975764 -
Fecal Microbiota in Preterm Birth
|
||
Completed |
NCT03219931 -
NEOBIFI: Clinical Trial for the Prevention and/or Reduction of the Incidence of Colics in Infants
|
Phase 4 | |
Recruiting |
NCT04466072 -
Gut Microbiome and Ventricular Arrhythmias
|
||
Recruiting |
NCT04447365 -
The Correlation Between Gut Microbiome-host Interaction and Ventricular Arrhythmias.
|
||
Not yet recruiting |
NCT06130137 -
Gut Microbiome in People Living With HIV and HBV
|
||
Recruiting |
NCT06260579 -
Home-based Exercise and Physical Activity Intervention After Kidney Transplantation: Impact of Exercise Intensity
|
N/A | |
Completed |
NCT04511052 -
Probiotics for Enhanced Tissue Carotenoid Status in Premenopausal Women
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06424691 -
Infant Restore: Efficacy of Microbiome Analysis and Education
|
N/A | |
Recruiting |
NCT06404749 -
Fungal Fiber for Gut Health
|
N/A |